Biden Administration Pause On Pending Trump-Era Rules Stalls FDA Cannabinoids Guidance Progress
Executive Summary
Among four FDA regulatory items withdrawn from OMB review is “Cannabidiol Enforcement Policy; Draft Guidance for Industry,” which the agency submitted in July 2020.
You may also be interested in...
Legislating US Regulatory Pathway For Cannabinoids ‘Not End of The World’ – Gottlieb
Former FDA commissioner says legislative carve-out for a regulatory pathway for cannabinoids is a better option than a rulemaking, which could take five years and “may not even work.” Cannabinoids market is “well far ahead of where the regulation is,” he says.
‘Regular Order’ Restored For Legislation To Make Cannabinoids Lawful Under FDA Regulations
De-scheduling provision in 2018 farm bill wasn’t crafted by House and Senate committees with FDA oversight, making it important that legislation to make hemp-derived cannabinoids lawful for use in supplements comes through House Energy and Commerce or Senate HELP committee.
Legislating Hemp As Dietary Ingredient: Wrapping US Market In A Bow, Or Tying DSHEA In Knots?
House legislation to exempt hemp-derived cannabinoids from FDA rule that an “article” previously studied or approved for use as drugs is not allowed for use in dietary supplements either resolves a conundrum or raises additional questions for the agency and the industry.